دورية أكاديمية
Optimizing drug development of anti-cancer drugs in children using modelling and simulation.
| العنوان: | Optimizing drug development of anti-cancer drugs in children using modelling and simulation. |
|---|---|
| المؤلفون: | van Hasselt JG; Department of Clinical Pharmacology, Netherlands Cancer Institute; Department of Pharmacy & Pharmacology, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, the Netherlands. jgc.vanhasselt@gmail.com, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD |
| المصدر: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2013 Jul; Vol. 76 (1), pp. 30-47. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: London, Macmillan Journals Ltd. |
| مواضيع طبية MeSH: | Drug Design*, Antineoplastic Agents/*pharmacology , Neoplasms/*drug therapy, Adult ; Age Factors ; Animals ; Antineoplastic Agents/administration & dosage ; Child ; Clinical Trials as Topic/methods ; Computer Simulation ; Dose-Response Relationship, Drug ; Drug Monitoring ; Humans ; Models, Biological ; Models, Molecular ; Neoplasms/pathology |
| مستخلص: | Modelling and simulation (M&S)-based approaches have been proposed to support paediatric drug development in order to design and analyze clinical studies efficiently. Development of anti-cancer drugs in the paediatric population is particularly challenging due to ethical and practical constraints. We aimed to review the application of M&S in the development of anti-cancer drugs in the paediatric population, and to identify where M&S-based approaches could provide additional support in paediatric drug development of anti-cancer drugs. A structured literature search on PubMed was performed. The majority of identified M&S-based studies aimed to use population PK modelling approaches to identify determinants of inter-individual variability, in order to optimize dosing regimens and to develop therapeutic drug monitoring strategies. Prospective applications of M&S approaches for PK-bridging studies have scarcely been reported for paediatric oncology. Based on recent developments of M&S in drug development there are several opportunities where M&S could support more informative bridging between children and adults, and increase efficiency of the design and analysis of paediatric clinical trials, which should ultimately lead to further optimization of drug treatment strategies in this population. (© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.) |
| References: | J Clin Pharm Ther. 2011 Apr;36(2):237-45. (PMID: 21366654) J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34. (PMID: 15379381) Int J Clin Pharmacol Ther. 2010 Jan;48(1):11-21. (PMID: 20040335) Ther Drug Monit. 2009 Feb;31(1):76-85. (PMID: 19077931) Bone Marrow Transplant. 2001 Oct;28(7):657-64. (PMID: 11704788) Clin Pharmacol Ther. 1996 Apr;59(4):436-43. (PMID: 8612389) Pediatr Blood Cancer. 2010 Mar;54(3):355-60. (PMID: 19731319) Paediatr Drugs. 2002;4(4):257-65. (PMID: 11960514) Cancer Chemother Pharmacol. 2003 Jun;51(6):465-73. (PMID: 12698270) J Pharmacokinet Pharmacodyn. 2003 Apr;30(2):145-61. (PMID: 12942685) Eur J Pediatr. 2006 Dec;165(12):819-29. (PMID: 16807729) Clin Exp Pharmacol Physiol. 2001 Nov;28(11):905-12. (PMID: 11703394) Haematologica. 2010 Jul;95(7):1106-13. (PMID: 20418240) J Clin Pharmacol. 2007 Oct;47(10):1231-43. (PMID: 17906158) Pharm Res. 2012 Jun;29(6):1609-17. (PMID: 22246291) Clin Pharmacol Ther. 2010 May;87(5):601-8. (PMID: 20376000) Eur J Cancer. 2012 Nov;48(16):3063-72. (PMID: 22742881) Malar J. 2011 Jul 01;10:181. (PMID: 21722356) Cancer Chemother Pharmacol. 2008 Nov;62(6):1027-37. (PMID: 18278496) Xenobiotica. 2013 Mar;43(3):276-82. (PMID: 22931186) Clin Cancer Res. 2011 Nov 1;17(21):6867-77. (PMID: 21918171) Mol Cancer Ther. 2006 Aug;5(8):1905-8. (PMID: 16928809) AAPS J. 2005 Oct 05;7(2):E475-87. (PMID: 16353925) J Clin Oncol. 2011 Sep 10;29(26):3529-34. (PMID: 21825264) J Clin Oncol. 1994 Mar;12(3):532-8. (PMID: 7907130) Cancer Chemother Pharmacol. 2011 Apr;67(4):875-90. (PMID: 20582417) Int J Clin Pharmacol Ther. 2010 May;48(5):327-34. (PMID: 20420789) Int J Clin Pharmacol Ther. 2002 Jun;40(6):270-8. (PMID: 12078941) Br J Clin Pharmacol. 2002 Apr;53(4):386-9. (PMID: 11966670) Clin Cancer Res. 2008 Jan 1;14(1):318-25. (PMID: 18172284) Antimicrob Agents Chemother. 2010 Jun;54(6):2626-32. (PMID: 20385872) Eur J Cancer. 2011 Jul;47(10):1556-63. (PMID: 21482104) Ther Drug Monit. 2008 Feb;30(1):75-83. (PMID: 18223466) Cancer Chemother Pharmacol. 2007 Sep;60(4):609-20. (PMID: 17195068) Dermatol Ther. 2009 May-Jun;22(3):257-61. (PMID: 19453350) Clin Pharmacol Ther. 2010 Mar;87(3):294-302. (PMID: 20107435) Clin Cancer Res. 2004 Aug 1;10(15):5072-5. (PMID: 15297409) Clin Pharmacokinet. 2001;40(8):615-25. (PMID: 11523727) Clin Pharmacol Ther. 2012 Jul;92(1):40-9. (PMID: 22669290) Cancer Chemother Pharmacol. 2012 Jul;70(1):83-94. (PMID: 22623208) Cancer Chemother Pharmacol. 2003 Sep;52(3):209-16. (PMID: 12811512) Clin Cancer Res. 2001 Aug;7(8):2301-8. (PMID: 11489805) Pediatr Hematol Oncol. 2012 Mar;29(2):154-65. (PMID: 22376019) Cancer Treat Rep. 1985 Nov;69(11):1263-9. (PMID: 2418966) Biologics. 2010 Jun 24;4:111-8. (PMID: 20631817) J Clin Oncol. 2009 Sep 1;27(25):4103-8. (PMID: 19636014) Ther Drug Monit. 2010 Apr;32(2):159-68. (PMID: 20110851) Med Pediatr Oncol. 1995 Apr;24(4):235-40. (PMID: 7700168) Br J Clin Pharmacol. 2009 Oct;68(4):493-501. (PMID: 19843052) Clin Pharmacokinet. 2012 May 1;51(5):319-30. (PMID: 22439649) Br J Clin Pharmacol. 2012 Dec;74(6):932-9. (PMID: 22452385) Clin Pharmacokinet. 1996 May;30(5):329-32. (PMID: 8743333) Cancer Chemother Pharmacol. 2003 Nov;52(5):417-23. (PMID: 12879279) J Clin Pharmacol. 2004 Nov;44(11):1309-22. (PMID: 15496649) Cancer Chemother Pharmacol. 2009 Jul;64(2):243-51. (PMID: 19020877) Cancer Chemother Pharmacol. 1996;37(3):195-202. (PMID: 8529278) Br J Clin Pharmacol. 2009 Oct;68(4):546-60. (PMID: 19843058) Pharm Res. 2012 Jun;29(6):1530-43. (PMID: 22350799) Cancer Chemother Pharmacol. 2011 Mar;67(3):597-603. (PMID: 20490798) Pharm Res. 2012 Dec;29(12):3499-511. (PMID: 22907417) Int J Mol Sci. 2012;13(1):1126-53. (PMID: 22312308) J Pediatr Hematol Oncol. 2007 Apr;29(4):239-47. (PMID: 17414566) Br J Clin Pharmacol. 2003 Oct;56(4):370-7. (PMID: 12968981) Cancer Chemother Pharmacol. 2003 Dec;52(6):435-41. (PMID: 13680158) J Neurooncol. 2012 Jan;106(1):135-41. (PMID: 21796446) Cancer Chemother Pharmacol. 2011 Nov;68(5):1191-8. (PMID: 21404110) Eur J Clin Pharmacol. 2011 May;67 Suppl 1:75-86. (PMID: 21246352) Pediatr Res. 2002 Jul;52(1):113-8. (PMID: 12084857) J Clin Pharmacol. 2008 Sep;48(9):1052-62. (PMID: 18635758) Ther Drug Monit. 2012 Apr;34(2):198-208. (PMID: 22406655) J Clin Oncol. 2002 Dec 15;20(24):4713-21. (PMID: 12488418) Cancer Chemother Pharmacol. 1996;39(1-2):42-50. (PMID: 8995498) Clin Pharmacol Ther. 2012 May;91(5):926-31. (PMID: 22472993) Cancer Chemother Pharmacol. 2002 Nov;50(5):373-82. (PMID: 12439595) Clin Cancer Res. 1997 May;3(5):713-7. (PMID: 9815740) Cancer Chemother Pharmacol. 2012 Feb;69(2):397-405. (PMID: 21789689) PLoS Comput Biol. 2010 Dec 02;6(12):e1001019. (PMID: 21152005) J Biomed Biotechnol. 2011;2011:907461. (PMID: 21716673) Blood. 2002 Mar 15;99(6):1986-94. (PMID: 11877270) Cancer Treat Rev. 2012 Feb;38(1):3-26. (PMID: 21489698) Pediatr Blood Cancer. 2011 Jul 15;57(1):41-6. (PMID: 21425443) Fundam Clin Pharmacol. 1999;13(5):595-604. (PMID: 10520733) Clin Pharmacokinet. 2012 May 1;51(5):331-45. (PMID: 22455797) Br J Clin Pharmacol. 2011 Sep;72(3):474-81. (PMID: 21453298) J Pharmacokinet Biopharm. 1993 Dec;21(6):735-50. (PMID: 8138894) Fundam Clin Pharmacol. 2008 Dec;22(6):599-604. (PMID: 19049661) Bone Marrow Transplant. 2004 May;33(10):979-87. (PMID: 15064687) Br J Haematol. 2010 Jan;148(1):119-25. (PMID: 19821822) Clin Pharmacol Ther. 2011 Jul;90(1):126-32. (PMID: 21633346) Ther Drug Monit. 2008 Aug;30(4):504-10. (PMID: 18641537) Cancer Chemother Pharmacol. 1982 Dec;10(1):22-6. (PMID: 6891625) AAPS J. 2011 Jun;13(2):230-9. (PMID: 21387147) Clin Pharmacokinet. 2012 Oct 1;51(10):671-9. (PMID: 23018530) Clin Pharmacokinet. 2011 Jul;50(7):461-9. (PMID: 21651313) Neuro Oncol. 2006 Apr;8(2):89-95. (PMID: 16461424) Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6703-11. (PMID: 18006771) Clin Pharmacokinet. 2010 Sep;49(9):619-32. (PMID: 20690784) Br J Clin Pharmacol. 2007 Aug;64(2):151-64. (PMID: 17324241) Ther Drug Monit. 2012 Oct;34(5):574-83. (PMID: 22972539) Anticancer Drugs. 2001 Feb;12(2):151-8. (PMID: 11261889) Cancer Chemother Pharmacol. 2009 Jan;63(2):229-38. (PMID: 18398615) Ann Pharmacother. 2002 Sep;36(9):1344-50. (PMID: 12196049) BMC Med Inform Decis Mak. 2008 Jan 28;8:6. (PMID: 18226244) Stat Methods Med Res. 1999 Sep;8(3):183-93. (PMID: 10636334) Clin Cancer Res. 2011 Jul 15;17(14):4862-71. (PMID: 21653689) Lancet. 1998 Nov 28;352(9142):1731-8. (PMID: 9848348) Br J Cancer. 2007 Feb 12;96(3):424-31. (PMID: 17224928) Cancer Chemother Pharmacol. 2005 May;55(5):433-8. (PMID: 15818507) Pediatrics. 2008 Mar;121(3):530-9. (PMID: 18310202) Eur J Clin Pharmacol. 2011 Oct;67(10):993-1006. (PMID: 21509569) J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):195-203. (PMID: 22311388) J Clin Pharmacol. 2007 Jan;47(1):101-11. (PMID: 17192508) Pediatr Blood Cancer. 2009 Dec 15;53(7):1195-9. (PMID: 19621434) Clin Pharmacol Ther. 2009 Aug;86(2):136-8. (PMID: 19621009) J Pharm Sci. 2010 Jul;99(7):2927-33. (PMID: 20127826) Clin Pharmacol Ther. 2010 Aug;88(2):166-82. (PMID: 20613720) J Clin Pharmacol. 2009 Jan;49(1):88-102. (PMID: 18927240) J Clin Oncol. 1998 Jan;16(1):181-6. (PMID: 9440741) Clin Pharmacokinet. 2006;45(12):1227-38. (PMID: 17112298) Br J Clin Pharmacol. 2008 Dec;66(6):826-37. (PMID: 18823306) Bone Marrow Transplant. 1996 Nov;18(5):843-50. (PMID: 8932835) Anticancer Drugs. 2002 Jan;13(1):101-10. (PMID: 11914647) Handb Exp Pharmacol. 2011;205:111-24. (PMID: 21882108) Ther Drug Monit. 2007 Apr;29(2):177-84. (PMID: 17417071) |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20121211 Date Completed: 20140203 Latest Revision: 20211021 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3703226 |
| DOI: | 10.1111/bcp.12062 |
| PMID: | 23216601 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2125 |
|---|---|
| DOI: | 10.1111/bcp.12062 |